Jan Jong Hung | Lung Cancer | Editorial Board Member

Published on by Biotechnology Scientist

Prof. Jan Jong Hung | Lung Cancer | Editorial Board Member

Professor at College of Bioscience and Biotechnology, National Cheng Kung University | Taiwan

Prof. Jan-Jong Hung is a highly accomplished biotechnology and cancer biology researcher whose extensive contributions make him exceptionally suitable for an Editorial Board Member role. His work centers on basic and translational lung cancer research, with strong expertise in protein post-translational modifications, genomic instability, ER stress, autophagy, cell death pathways, and mechanisms of drug resistance. Dr. Hung has produced a substantial body of influential research, including landmark studies on USP24, PD-1 stability, ferroptosis, EGFR-related oncogenesis, and ubiquitin-mediated regulatory mechanisms that shape cancer progression and therapeutic response. His publication record spans more than 60 peer-reviewed articles in top-tier journals such as Science Advances, Cell Death & Disease, Cell Death & Differentiation, Nature Communications, Oncogene, Journal of Biomedical Science, and Molecular Oncology. These works highlight his leadership in elucidating molecular determinants of lung cancer malignancy and developing novel therapeutic strategies. In addition to his scholarly contributions, he holds multiple high-impact patents on USP24 inhibitors and anticancer drug-resistance modulation technologies, demonstrating strong translational vision. Collectively, his scientific depth, innovation, and editorial experience strongly support his suitability for an Editorial Board Member position in leading biotechnology and cancer research platforms.

Profile : ORCID

Featured Publications

Wang, Y.-S., Young, M.-J., Liu, C.-Y., Chen, Y.-C., & Hung, J.-J. (2023). Tp53 haploinsufficiency is involved in hotspot mutations and cytoskeletal remodeling in gefitinib-induced drug-resistant EGFRL858R-lung cancer mice. Cell Death Discovery.

Young, M.-J., Chen, Y.-C., Wang, S.-A., Chang, H.-P., Yang, W.-B., Lee, C.-C., Liu, C.-Y., Tseng, Y.-L., Wang, Y.-C., Sun, H. S., & Hung, J.-J. (2022). Estradiol-mediated inhibition of Sp1 decreases miR-3194-5p expression to enhance CD44 expression during lung cancer progression. Journal of Biomedical Science.

Chen, Y.-C., Young, M.-J., Chang, H.-P., Liu, C.-Y., Lee, C.-C., Tseng, Y.-L., Wang, Y.-C., Chang, W.-C., & Hung, J.-J. (2022). Estradiol-mediated inhibition of DNMT1 decreases p53 expression to induce M2-macrophage polarization in lung cancer progression. Oncogenesis.

Wang, S.-A., Young, M.-J., Wang, Y.-C., Chen, S.-H., Liu, C.-Y., Lo, Y.-A., Jen, H.-H., Hsu, K.-C., & Hung, J.-J. (2021). USP24 promotes drug resistance during cancer therapy. Cell Death & Differentiation.

Wang, S.-A., Young, M.-J., Jeng, W.-Y., Liu, C.-Y., & Hung, J.-J. (2020). USP24 stabilizes bromodomain containing proteins to promote lung cancer malignancy. Scientific Reports.